Last reviewed · How we verify
Excessive salivation
Approved treatments
- (-)-Atropine · University of Kansas Medical Center
- Cuvposa · Shionogi
Cuvposa works by blocking the action of a chemical called acetylcholine, which stimulates the muscarinic receptors in the body. - Glycopyrrolate · Yonsei University
- Sialanar · Proveca Pharma Limited
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Excessive salivation patent landscape — cliff calendar, originator estates, attackable patents
- Excessive salivation treatment landscape brief
- Excessive salivation treatment updates RSS
Frequently asked questions about Excessive salivation
What drugs treat Excessive salivation?
Tracked treatments include (-)-Atropine, Cuvposa, Glycopyrrolate, Sialanar.
What is the treatment for Excessive salivation?
Standard treatment for Excessive salivation includes (-)-Atropine, Cuvposa, Glycopyrrolate, Sialanar. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Excessive salivation patent cliff · Excessive salivation CI report
- Treatment: (-)-Atropine · University of Kansas Medical Center
- Treatment: Cuvposa · Shionogi
- Treatment: Glycopyrrolate · Yonsei University
- Treatment: Sialanar · Proveca Pharma Limited
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing